| __timestamp | MiMedx Group, Inc. | Pharming Group N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 7050000 | 14182353 |
| Thursday, January 1, 2015 | 8413000 | 15503028 |
| Friday, January 1, 2016 | 12038000 | 16183585 |
| Sunday, January 1, 2017 | 17900000 | 22382849 |
| Monday, January 1, 2018 | 15765000 | 33038206 |
| Tuesday, January 1, 2019 | 11140000 | 31777040 |
| Wednesday, January 1, 2020 | 11715000 | 41464134 |
| Friday, January 1, 2021 | 17344000 | 67178053 |
| Saturday, January 1, 2022 | 22829000 | 52531000 |
| Sunday, January 1, 2023 | 12665000 | 68914000 |
Unleashing the power of data
In the ever-evolving world of biotechnology, research and development (R&D) expenses are a key indicator of a company's commitment to innovation. Over the past decade, Pharming Group N.V. and MiMedx Group, Inc. have demonstrated contrasting strategies in their R&D investments.
Pharming Group N.V. has consistently outpaced MiMedx Group, Inc. in R&D spending, with a notable peak in 2023, where their expenses reached nearly 69 million, marking a 385% increase from 2014. This robust investment underscores Pharming's aggressive pursuit of new therapies and technologies.
Conversely, MiMedx Group, Inc. has shown a more conservative approach, with R&D expenses peaking in 2022 at approximately 23 million, a 224% rise from 2014. This reflects a more measured strategy, focusing on optimizing existing products.
These spending patterns highlight the diverse approaches within the biotech sector, where innovation is the lifeblood of progress.
Merck & Co., Inc. or MiMedx Group, Inc.: Who Invests More in Innovation?
R&D Insights: How Amgen Inc. and Pharming Group N.V. Allocate Funds
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs MiMedx Group, Inc.
Research and Development: Comparing Key Metrics for Summit Therapeutics Inc. and MiMedx Group, Inc.
Research and Development Investment: Pharming Group N.V. vs Amicus Therapeutics, Inc.
Research and Development Investment: Pharming Group N.V. vs Catalyst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Pharming Group N.V. and MorphoSys AG
Research and Development Expenses Breakdown: Pharming Group N.V. vs Arrowhead Pharmaceuticals, Inc.
R&D Spending Showdown: Pharming Group N.V. vs Amphastar Pharmaceuticals, Inc.
Analyzing R&D Budgets: Pharming Group N.V. vs Travere Therapeutics, Inc.
Research and Development Expenses Breakdown: Pharming Group N.V. vs Taro Pharmaceutical Industries Ltd.
R&D Insights: How ADMA Biologics, Inc. and MiMedx Group, Inc. Allocate Funds